{"filing":{"accession_number":"0001213900-26-068251","cik":"0001892500","ticker":"CMND","company_name":"Clearmind Medicine Inc.","form":"6-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294592-6k_clearmind.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1892500/000121390026068251/ea0294592-6k_clearmind.htm"},"events":[{"id":12161,"run_id":10723,"accession_number":"0001213900-26-068251","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"This exhibit discloses an agreement for the Company to issue $1,000,000 in aggregate principal amount of convertible promissory notes to accredited investors at a 10% discount ($900,000 purchase price). Convertible notes are dilutive securities that can convert to common shares, and the agreement also amends the conversion price floor to $1.875 per share. This is a private placement of convertible debt that will dilute existing shareholders upon conversion, fitting the dilutive_issuance category.","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-12","form":"6-K","submitted_at":null,"items":[{"id":8943,"accession_number":"0001213900-26-068251","item_number":"EX-99.1","item_title":"ea029459201ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This exhibit discloses an agreement for the Company to issue $1,000,000 in aggregate principal amount of convertible promissory notes to accredited investors at a 10% discount ($900,000 purchase price). Convertible notes are dilutive securities that can convert to common shares, and the agreement also amends the conversion price floor to $1.875 per share. This is a private placement of convertible debt that will dilute existing shareholders upon conversion, fitting the dilutive_issuance category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:20:24.520268+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8943,"accession_number":"0001213900-26-068251","item_number":"EX-99.1","item_title":"ea029459201ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"This exhibit discloses an agreement for the Company to issue $1,000,000 in aggregate principal amount of convertible promissory notes to accredited investors at a 10% discount ($900,000 purchase price). Convertible notes are dilutive securities that can convert to common shares, and the agreement also amends the conversion price floor to $1.875 per share. This is a private placement of convertible debt that will dilute existing shareholders upon conversion, fitting the dilutive_issuance category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:20:24.520268+00:00","company_name":"Clearmind Medicine Inc.","ticker":"CMND","filing_date":"2026-06-12"}]}